We have an exciting pipeline of compounds, some you know about and some you don't yet. And lastly, we have substantial capital to make thoughtful capital allocation decisions. This is a unique and very good spot to be in, in the current environment, and that brings me back to where I started, the tremendous market success of ORLADEYO. The steady and consistent revenue growth, disciplined and objective decision-making on capital allocation and alternative financing sources like the additional debt from Athyrium recently drew down are the things that give us confidence we can repeat the ORLADEYO success with other molecules and create much greater value in the process.